Allosteric Site

Overview

An allosteric site is a topographically and functionally distinct binding pocket on a protein, separate from the orthosteric (primary) site where the natural substrate or agonist binds. Allosteric site occupancy induces conformational changes that transmit across the protein to alter orthosteric site properties — binding affinity, catalytic efficiency, or signaling output.

Allosteric sites are prized in drug design because they offer selectivity advantages over orthosteric sites, which tend to be highly conserved across protein families. The related functional concept is explored in detail in allosteric modulation.

Detailed Explanation

Structural basis

Allosteric sites are physical pockets on the protein surface or inside its tertiary structure. They can be:

• Preformed — visible in ligand-free crystal structures
• Cryptic — appearing only in certain conformational states
• Induced — forming upon ligand binding through conformational rearrangement

Identifying allosteric sites often requires a combination of biophysical methods: cryo-EM, NMR dynamics, molecular dynamics simulations, covalent fragment screening, and large-scale mutagenesis.

Coupling to the orthosteric site

Binding at the allosteric site produces conformational changes that propagate through:

• Rigid body motions — domain rearrangements
• Loop rearrangements — especially activation loops in kinases
• Altered dimer/oligomer interfaces
• Changes in intrinsic disorder — folding or unfolding of specific regions

This conformational coupling modulates substrate binding, competitive inhibition profiles, or downstream signaling.

Advantages of Targeting Allosteric Sites

• Selectivity — Allosteric pockets diverge much more across protein families than conserved orthosteric sites.
• Ceiling effects — Allosteric modulators have natural maxima because they amplify or dampen endogenous ligand without replacing it.
• Preservation of physiological timing — Modulators act only when endogenous ligand is present.
• Probe-dependent tuning — Different modulators can cooperate with the same receptor in divergent ways, a hallmark of biased agonism.
• Overcoming orthosteric resistance mutations — Useful in oncology against kinase inhibitor-resistant mutants.

Types of Allosteric Modulators

• Positive allosteric modulators (PAMs) — increase orthosteric affinity and/or efficacy
• Negative allosteric modulators (NAMs) — decrease orthosteric affinity and/or efficacy
• Silent allosteric modulators (SAMs) — bind without altering orthosteric ligand response but block other modulators
• Allosteric agonists — activate the receptor directly from the allosteric site
• Bitopic ligands — span orthosteric and allosteric sites simultaneously

Allosteric Sites in Major Drug Targets

• Kinases — Type II (DFG-out), Type III (non-ATP-competitive) inhibitors target allosteric pockets. Trametinib (MEK) and SHP2 inhibitors are notable examples.
• G-protein-coupled receptors — Calcimimetics (cinacalcet) for calcium-sensing receptor; maraviroc for CCR5.
• Enzymes — Fructose-1,6-bisphosphate modulates pyruvate kinase; citrate regulates phosphofructokinase.
• Nuclear receptors — F-domain and other secondary pockets.
• Ion channels — Benzodiazepines on GABA-A receptors.

Peptide Allosteric Modulators

Peptides can bind allosteric sites through:

• Exosite engagement — thrombin inhibitors like bivalirudin span active and exosite I
• Dimerization-interface peptides that disrupt receptor homo- or heterodimers
• Intracellular loop-mimetic peptides modulating GPCR-G protein coupling

The ability of peptides to cover large surface areas makes them especially suited to allosteric strategies where a small molecule cannot generate sufficient contacts.

Measurement

• Radioligand binding — detect shifts in orthosteric Kd
• Functional assays — observe dose-response curve shifts in amplitude or EC50
• Operational model fitting — extract binding cooperativity and efficacy modulation
• Biophysical methods — SPR, NMR, HDX-MS to see conformational changes directly

Summary

An allosteric site is any ligand-binding site on a protein outside the primary substrate or agonist pocket. Targeting such sites offers selectivity, ceiling effects, and signaling nuance impossible at orthosteric sites, and is a cornerstone of modern peptide and small-molecule drug design.